Chinese Academy of Medical Sciences

🇨🇳China
Ownership
Private, Subsidiary
Established
2004-07-08
Employees
-
Market Cap
-
Website
http://www.pinganzhengxing.com
Clinical Trials
Related News

Tomotherapy for Leptomeningeal Metastases

Not Applicable
Completed
Conditions
Leptomeningeal Metastasis
Interventions
Radiation: tomotherapy
First Posted Date
2019-11-26
Last Posted Date
2019-11-26
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
103
Registration Number
NCT04178343
Locations
🇨🇳

Chinese Academy of Medical Sciences, Beijing, Beijing, China

Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

First Posted Date
2019-11-08
Last Posted Date
2020-04-24
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
3000
Registration Number
NCT04158505
Locations
🇨🇳

National Cancer Center, Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

First Posted Date
2019-10-25
Last Posted Date
2022-03-11
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
60
Registration Number
NCT04140318
Locations
🇨🇳

Chinese Academy of Medical Sciences, Beijing, China

Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma

Phase 1
Completed
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Drug: Sintilimab+IBI305
First Posted Date
2019-08-28
Last Posted Date
2021-02-01
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
50
Registration Number
NCT04072679
Locations
🇨🇳

National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College, Beijing, China

Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

First Posted Date
2019-07-25
Last Posted Date
2019-07-25
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
40
Registration Number
NCT04033172
Locations
🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.

First Posted Date
2019-07-18
Last Posted Date
2019-12-11
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
30
Registration Number
NCT04023916

Monitoring Efficacy of Radiotherapy in Lung Cancer and Esophageal Cancer

First Posted Date
2019-07-10
Last Posted Date
2021-02-02
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
150
Registration Number
NCT04014465
Locations
🇨🇳

Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical sciences, Beijing, Beijing, China

PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer

First Posted Date
2019-06-03
Last Posted Date
2019-06-04
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
6
Registration Number
NCT03971214
Locations
🇨🇳

Cancer Insititute and Hosiptal of Chinese Academy of Medical Sciences, Beijing, Beijing, China

Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR

First Posted Date
2019-05-13
Last Posted Date
2019-05-14
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
200
Registration Number
NCT03947736
Locations
🇨🇳

Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

First Posted Date
2019-05-07
Last Posted Date
2020-06-23
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
30
Registration Number
NCT03939871
Locations
🇨🇳

National Cacner Center/ Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy